Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 1.3 billion people worldwide and is frequently associated with cardiovascular disease, type 2 diabetes, chronic kidney disease, and other metabolic disorders. A key feature linking these conditions is metabolic inflammation, or metainflammation, a state of chronic, low-grade inflammation driven by excessive lipid accumulation and adipose tissue dysfunction. Metainflammation promotes hepatic steatosis, inflammation, hepatocyte injury and ballooning, and fibrosis, thereby contributing to the development and progression of MASLD, as well as metabolic dysfunction and alcohol-associated liver disease (MetALD), which can lead to liver cirrhosis and hepatocellular carcinoma. These pathological processes are mediated through multiple interconnected mechanisms, including insulin resistance, dysregulated lipid metabolism, oxidative stress, fibrogenesis, and alterations in the gut microbiota. This review discusses the mechanisms underlying metainflammation in MASLD and MetALD and summarizes current and emerging therapeutic strategies targeting these pathogenic factors in preclinical studies and clinical trials.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: